Related Experiment Video
Updated: Aug 13, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Rates of Neisseria meningitidis increasing in young adults
Sunanda Gaur1, Amisha Malhotra, Patricia Whitley-Williams
1Division of Allergy, Immunology, and Infectious Diseases, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
Abstract:
The burden of meningococcal disease has remained unchanged in the United States for the past 4 decades. The currently available meningococcal vaccine is safe and effective, however, due to immunogenic limitations inherent to polysaccharide vaccines, it has been available only for high-risk populations older than 2. Incorporation of a more immunogenic and effective conjugated vaccine into the routine immunization schedule offers an opportunity to substantially affect the incidence of meningococcal disease. The routine use of a meningococcal conjugate vaccine in the United States will save lives and prevent significant morbidity in children and young adults.
Related Concept Videos
Bacterial Meningitis
Viral Meningitis
Arboviral Encephalitis
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology
Encephalitis l: Introduction

